Feb 13, 2019
Cancer Research Pioneer Dr. H. Michael Shepard Joins Anpac Bio Technical Advisory Board
Feb 07, 2019
Paramount Developments Crucial for Advancing Clinical Trials Targeting Cancer Treatments
Jan 17, 2019
New Pathology Guideline Advances Accuracy in Breast Cancer Testing
Jan 14, 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Dec 21, 2018
Oxford BioTherapeutics Receives US FDA IND Clearance for OBT076
Dec 10, 2018
Beating Cancer Begins with Targeted Therapy
Dec 08, 2018
Daiichi Sankyo Presents Updated Phase 1 Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Low Expressing Metastatic Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)
Dec 07, 2018
New Studies Show MammaPrint® and BluePrint® Tests Provide Greater Clarity Regarding Risk of Breast Cancer Recurrence and Classifications for Treatment
Dec 05, 2018
Daiichi Sankyo Presents Updated Phase 1 Data for U3-1402 in Patients with HER3-Expressing Metastatic Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)
Dec 04, 2018
uBiome Announces First Stage of Companion Diagnostic Development in Collaboration with Puma Biotechnology, Inc.
Nov 28, 2018
Agendia Announces New Research Reinforcing MammaPrint® and BluePrint® Testing to Guide Breast Cancer Treatment Management Decisions Across Different Patient Populations and Ages at the 2018 San Antonio Breast Cancer Symposium
Nov 28, 2018
U.S./Australian Study Highlights Rapid Analysis and Clinical Utility of Liquid Biopsy Assay
Nov 27, 2018
Generex Biotechnology Signs Clinical Trial Agreement With the NSABP Foundation, Inc. for Phase II Clinical Trial of AE37 in Combination With Pembrolizumab (Keytruda®) for Treatment of Triple-Negative Breast Cancer
Nov 27, 2018
Daiichi Sankyo and Roche to Collaborate on New HER2 Low Companion Diagnostic Test
Oct 22, 2018
Kazia Enters Clinical Collaboration to Investigate Use of Brain Cancer Drug GDC-0084 in Breast Cancer
Oct 21, 2018
Daiichi Sankyo Presents Updated Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Expressing Advanced Colorectal Cancer at 2018 European Society for Medical Oncology (ESMO) Congress
Oct 19, 2018
Mylan and Biocon Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab
Oct 19, 2018
Menarini Progresses Into the Clinic With MEN1611, a PI3K Inhibitor for the Treatment of HER2 Positive Metastatic Breast Cancer
Oct 19, 2018
Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility
Oct 16, 2018
Alphamab Oncology's HER2 bispecific antibody KN026 gained US IND approval; phase I clinical trial started in China